Explore the Agenda
8:30 am Registration & Light Breakfast
9:20 am Chair’s Opening Remarks
Advancing Next-Generation Technologies to De-Risk Development & Expedite the Evaluation of Novel Therapeutic Strategies
9:30 am A Novel Approach for Glioma Therapy: Targeting Cell Membrane Lipids with Melitherapy
- Innovating Melitherapy as a platform that specifically targets lipids within the cell membrane, offering a unique approach that contrasts with traditional protein-focused drug design
- Using synthetic fatty acids to modify the composition and fluidity of the cell membrane, which interferes with membrane-associated proteins responsible for disease processes like tumor growth
- Sharing MIN-001-1203 trial of 2-hydroxyoleic acid in patients with advanced solid tumors, including malignant glioma, has shown very promising results, highlighting the potential for significant clinical benefit
10:00 am Surmounting Barriers in Non-resectable Recurrent Glioblastoma with a Single Treatment of Bizaxofusp, an Engineered IL-4R Directed Fusion Protein
- Highlight the necessity of combining intratumoral delivery with the multi-pronged MoA to substantially extend survival in non-resectable rGBM patients
- Integrating paired patient biopsies, intratumoral drug distribution, and patient-derived organoid models to interrogate MoA and support clinical observations
- Scrutinize historical survival outcomes in non-resectable rGBM and their implication on applying external control arms in contemporary clinical trial design
10:30 am Morning Refreshments & Networking
11:00 am AI-Enabled Drug Discovery & Development for Glioblastoma
- Discussing how artificial intelligence is being used to analyze complex genomic, proteomic, and clinical data to identify novel drug targets and accelerate the discovery of new therapies for glioblastoma
- Optimizing clinical trial design and patient stratification, helping to identify the right patients for specific treatments and accelerate the path to regulatory approval
- Highlighting how machine learning models are being developed to predict individual patient response to different therapies, enabling personalized treatment strategies and improving outcomes in this difficult-to-treat cancer
11:30 am Assessing the Current in Engineered Rodent Models of GBM to Align with Regulatory Requirements
- Evaluating the utility of genetically engineered mouse models, xenograft cell lines, and syngeneic models to determine their relevance and effectiveness in glioblastoma research
- Learning how to use these advanced models to accurately simulate the glioblastoma microenvironment and enhance the effectiveness of preclinical drug testing
- Identifying the most suitable modelling approaches for ensuring that preclinical findings are reliable and can be successfully translates into clinical applications
12:00 pm Amplifying the GBM Family Voice: Real-Time Insights to Accelerate Trial Design and Enrollment
- Sharing how the GBM AI Agent—an anonymized, real-time support platform engages thousands of glioblastoma families worldwide
- Capturing the lived experience behind treatment choices, clinical trial interest, and barriers to participation
- These insights act as a continuous, global focus group, offering researchers, biotech, and advocacy leaders actionable intelligence to refine trial design, strengthen recruitment, and ensure cutting-edge therapies reach the patients who need them most
12:30 pm Lunch & Networking
1:30 pm Installing GPS on CAR T Cells: First-in-Human Phase I Trial of 8R-70CAR in Glioblastoma
- First-in-human Phase I clinical trial of 8R-70CAR T cells in GBM
- Novel IL-8 receptor “GPS” design to improve CAR T cell trafficking
- Early clinical signals of extended survivals
2:00 pm Advancing the Use of Cancer Vaccines in Glioblastoma to Reprogram the Patient’s Immune System
- Discussing the importance of tumor antigen selection and balanced immunity in vaccine design
- Addressing the tumor microenvironment to enhance cancer vaccines
Advancing Novel Modalities in Glioblastomas
2:30 pm Advancing the Use of Cancer Vaccines in Glioblastoma to Reprogram the Patient’s Immune System
- Designing vaccines to prime and activate the patient’s own immune system to recognize and attack specific GBM cells
- Identifying and utilizing GBM specific tumor antigens to develop targeted and effective vaccine strategies
- Focussing on GBM vaccines in combination with other modalities to overcome the TME and boost anti-tumor response